Blood-thinning drugs may slow Alzheimer's progress by improving brain blood flow

Millions of Britons take a specific medication daily for their heart health, and new research suggests this common drug might also help slow Alzheimer's disease. The study points to blood-thinning pills as the key player. These tablets are routinely prescribed to over 1.6 million patients across the UK who live with atrial fibrillation, a frequent heart rhythm disorder. This condition hits older adults hardest, and those at risk of dementia or already suffering from memory loss often fall into this group.

Swedish researchers have now concluded that these blood-thinning drugs could help slow cognitive decline in Alzheimer's patients by boosting blood flow to the brain. Yet, there is a catch. The team stopped short of advising anyone without atrial fibrillation to start taking them just for dementia prevention. Furthermore, the benefits only showed up in people using newer types of blood thinners.

This news could be huge for the roughly one million people currently living with dementia in the UK, where Alzheimer's is the most common form. That number is expected to climb to 1.4 million by 2040. Writing in the European Heart Journal, Dr Maria Eriksdotter, who led the study, said: 'There are reasons to believe that the treatment could have a positive effect on cognition, by improving blood flow and reducing small-scale damage in the brain.'

The investigation was conducted by experts at Karolinska University Hospital. They dug into data covering 7,308 people with both atrial fibrillation and Alzheimer's from the Swedish Register for Cognitive Disorders. The participants were sorted based on their medication choices: some took newer anticoagulants like rivaroxaban, others stuck with warfarin, an older version of the drug, and a third group took no anticoagulant at all.

Researchers tracked brain health using tests that measured memory, language skills, and motor abilities. The results were clear enough to note. Those on newer anticoagulants saw their cognitive function decline more slowly compared to people on warfarin or those taking nothing. Experts admit the difference was slight, but it is a step forward in understanding how to manage this growing crisis.

If you are worried about symptoms, consider checking with the Alzheimer's Society. Their Dementia Support Line is available at 0333 150 3456 for confidential advice. You can also use their symptoms checker to spot warning signs early. It is vital to look out for these indicators before it becomes too late.

Newer blood-thinning drugs showed an average memory boost of just under one percent after a full year of use. Researchers say that small gap might look tiny today but grows much larger over time. Professor Nanbo Zhu, who co-authored the study, explained this shift clearly. He noted that while the effect is modest for any single person in one year, even such an influence could change how cognitive function develops across a longer period.

Patients taking these modern anticoagulants faced lower risks of premature death, stroke, and fractures compared to those not on treatment. Warfarin also cut down death, stroke, and blood clot risks versus no treatment at all, yet it carried a higher chance of major bleeding. Scientists warn that more studies are needed before doctors prescribe these drugs solely based on expected benefits.

Atrial fibrillation happens when faulty electrical signals mess up the heart's rhythm. Studies link this condition to high blood pressure. It also hits harder in people over 55, men, those carrying extra weight, and smokers. This heart trouble can raise dementia risk by as much as a third. These findings follow news from NYU Langone Health scientists about three midlife health measures that fight off dementia for over ten years.

Keeping blood pressure normal, avoiding diabetes, and staying away from cigarettes between ages 45 and 65 tied into roughly thirteen extra years free of dementia. Dr Josef Coresh, the study's lead author, emphasized this point strongly. He argued that people must actively stop these risk factors in midlife to protect brain health for more than a decade. Hopefully, these results will push folks to quit smoking and watch their vascular health closely starting at age 45.